ut-logo website  
Register and login to access premium content
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

SUO 2013

14th Annual Meeting of the Society of Urologic Oncology (SUO)suo

December 4 - 6, 2013

Bethesda, MD USA

SUO 2013 - Abstract and Poster: Impact of prior docetaxel on sipuleucel-T product parameters in PROCEED patients

BETHESDA, MD USA (UroToday.com) - Introduction and Objectives: Sipuleucel-T is an autologous cellular immunotherapy indicated for asymptomatic or minimally symptomatic mCRPC.

Read more...

SUO 2013 - Abstract and Poster: NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer: Updated analysis of product parameters, HER2 expression and safety

BETHESDA, MD USA (UroToday.com) - Introduction and Objectives: HER2 overexpression in high-risk UC patients may be a negative prognostic factor.

Read more...

SUO 2013 - Session Highlights (Best Abstract Presentation): Experience with active surveillance (AS) in patients with renal mass > 4cm: Assessment of growth kinetics and outcomes

BETHESDA, MD USA (UroToday.com) - Dr. Reza Mehrazin and colleagues from Fox Chase Cancer Center presented one of the largest series of active surveillance in renal masses > 4cm.>

Read more...

SUO 2013 - Session Highlights: Evaluation of surveillance guidelines for renal cell carcinoma following partial nephrectomy

BETHESDA, MD USA (UroToday.com) - The numerous available strategies for surveillance following partial nephrectomy (PN) differ in both frequency and recommended imaging modalities.

Read more...

SUO 2013 - Session Highlights: Targeted magnetic resonance imaging/ultrasound fusion biopsy significantly outperforms random 12-core biopsy for prediction of total prostate cancer tumor volume

BETHESDA, MD USA (UroToday.com) - Targeted magnetic resonance imaging/ultrasound (MRI/US) fusion biopsy has been shown to allow for more optimal lesion targeting.

Read more...

SUO 2013 - Session Highlights: NEUACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer (UC): Updated analysis of product parameters, HER2 expression and safety

BETHESDA, MD USA (UroToday.com) - Dr. Leonard Gomella, professor and chairman of department urology at Thomas Jefferson University, presented an updated analysis on a multicenter, phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2 (negative prognostic factor) UC.

Read more...

SUO 2013 - Session Highlights: The influence of race on RCC incidence and survival

BETHESDA, MD USA (UroToday.com) - The incidence of renal cell carcinoma (RCC) has clearly increased over the last decade, and some of this might be attributed to increased abdominal imaging and incidentalomas.

Read more...

SUO 2013 - Session Highlights: Comparative effectiveness research studies of robotic vs. open prostatectomy

BETHESDA, MD USA (UroToday.com) - William Lowrance, MD, MPH reviewed some of the data regarding robotic and open prostatectomy.

Read more...

SUO 2013 - Session Highlights: Multicenter retrospective experience in the surgical management of isolated nodal recurrences post-nephrectomy in patients with renal cell carcinoma

BETHESDA, MD USA (UroToday.com) - Up to 10-24% of patients treated surgically for clinically localized renal cell carcinoma can recur locally.

Read more...

SUO 2013 - Session Highlights: Prostate cancer microparticles as a next generation screening tool for prostate cancer

BETHESDA, MD USA (UroToday.com) - Dr. Khurram Siddiqui presented her project evaluating prostate cancer microparticles as a screening tool for prostate cancer detection.

Read more...

Page 1 of 5